Prostate cancer is a male androgen-dependent tumor. Androgen stimulates the growth of prostate cancer cells and induces disease progression. Metastatic prostatectomy (ADT) is commonly used in patients with metastatic prostate cancer. The initial response rate can reach 80%-90%, but almost all patients will eventually progress to metastatic castration-resistant prostate… Continue Reading Competition pattern of new drug development in advanced prostate cancer

  On February 14, Merck announced the interim results of the Ib/II umbrella study KEYNOTE-365 at the American Society of Clinical Oncology Urology Tumor Symposium (ASCO GU). KEYNOTE-365 is a developmental, multicenter, multi-cohort, non-randomized study evaluating the efficacy of a fixed dose of Keytruda (200 mg once every 3 weeks)… Continue Reading Merck initiates the largest clinical trial of PD-1/PD-L1 prostate cancer